Neuroendocrine Carcinoma Market Report

Global and Region Neuroendocrine Carcinoma Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：231
  • REPORT CODE：GMM971452
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Neuroendocrine Carcinoma market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Neuroendocrine Carcinomamarket, defines the market attractiveness level of Neuroendocrine Carcinoma market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Neuroendocrine Carcinoma industry, describes the types of Neuroendocrine Carcinoma market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neuroendocrine Carcinoma market and the development prospects and opportunities of Neuroendocrine Carcinoma industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neuroendocrine Carcinoma market in Chapter 13.

    By Player:

    • Pfizer

    • FHoffmann-La Roche

    • Lexicon

    • Teva

    • Ipsen

    • Abbvie

    • Jubilant

    • Chiasma

    • Novartis

    • Mateon

    • Advanced Accelerator

    • Valeant

    By Type:

    • Chemotherapy

    • Somatostatin Analogs

    • Targeted Therapy

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Neuroendocrine Carcinoma Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Neuroendocrine Carcinoma Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Neuroendocrine Carcinoma Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Neuroendocrine Carcinoma Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Neuroendocrine Carcinoma Market Analysis and Outlook to 2022

    • 7.1 Global Neuroendocrine Carcinoma Consumption (2017-2022)

    • 7.2 United States Neuroendocrine Carcinoma Consumption (2017-2022)

    • 7.3 Europe Neuroendocrine Carcinoma Consumption (2017-2022)

    • 7.4 China Neuroendocrine Carcinoma Consumption (2017-2022)

    • 7.5 Japan Neuroendocrine Carcinoma Consumption (2017-2022)

    • 7.6 India Neuroendocrine Carcinoma Consumption (2017-2022)

    • 7.7 South Korea Neuroendocrine Carcinoma Consumption (2017-2022)

    8 Region and Country-wise Neuroendocrine Carcinoma Market Analysis and Outlook to 2028

    • 8.1 Global Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    • 8.2 United States Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    • 8.3 Europe Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    • 8.4 China Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    • 8.5 Japan Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    • 8.6 India Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    • 8.7 South Korea Neuroendocrine Carcinoma Consumption Forecast (2022-2028)

    9 Global Neuroendocrine Carcinoma Market Outlook by Types and Applications to 2022

    • 9.1 Global Neuroendocrine Carcinoma Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Somatostatin Analogs Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Targeted Therapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neuroendocrine Carcinoma Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Neuroendocrine Carcinoma Market Outlook by Types and Applications to 2028

    • 10.1 Global Neuroendocrine Carcinoma Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Somatostatin Analogs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Neuroendocrine Carcinoma Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Neuroendocrine Carcinoma Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Neuroendocrine Carcinoma Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Neuroendocrine Carcinoma Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Neuroendocrine Carcinoma Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Neuroendocrine Carcinoma Market Competitive Analysis

    • 14.1 Pfizer

      • 14.1.1 Pfizer Company Details

      • 14.1.2 Pfizer Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Pfizer Neuroendocrine Carcinoma Product and Service

    • 14.2 FHoffmann-La Roche

      • 14.2.1 FHoffmann-La Roche Company Details

      • 14.2.2 FHoffmann-La Roche Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 FHoffmann-La Roche Neuroendocrine Carcinoma Product and Service

    • 14.3 Lexicon

      • 14.3.1 Lexicon Company Details

      • 14.3.2 Lexicon Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Lexicon Neuroendocrine Carcinoma Product and Service

    • 14.4 Teva

      • 14.4.1 Teva Company Details

      • 14.4.2 Teva Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Teva Neuroendocrine Carcinoma Product and Service

    • 14.5 Ipsen

      • 14.5.1 Ipsen Company Details

      • 14.5.2 Ipsen Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Ipsen Neuroendocrine Carcinoma Product and Service

    • 14.6 Abbvie

      • 14.6.1 Abbvie Company Details

      • 14.6.2 Abbvie Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Abbvie Neuroendocrine Carcinoma Product and Service

    • 14.7 Jubilant

      • 14.7.1 Jubilant Company Details

      • 14.7.2 Jubilant Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Jubilant Neuroendocrine Carcinoma Product and Service

    • 14.8 Chiasma

      • 14.8.1 Chiasma Company Details

      • 14.8.2 Chiasma Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Chiasma Neuroendocrine Carcinoma Product and Service

    • 14.9 Novartis

      • 14.9.1 Novartis Company Details

      • 14.9.2 Novartis Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Novartis Neuroendocrine Carcinoma Product and Service

    • 14.10 Mateon

      • 14.10.1 Mateon Company Details

      • 14.10.2 Mateon Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Mateon Neuroendocrine Carcinoma Product and Service

    • 14.11 Advanced Accelerator

      • 14.11.1 Advanced Accelerator Company Details

      • 14.11.2 Advanced Accelerator Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Advanced Accelerator Neuroendocrine Carcinoma Product and Service

    • 14.12 Valeant

      • 14.12.1 Valeant Company Details

      • 14.12.2 Valeant Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Valeant Neuroendocrine Carcinoma Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Neuroendocrine Carcinoma

    • Figure Neuroendocrine Carcinoma Picture

    • Table Global Neuroendocrine Carcinoma Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuroendocrine Carcinoma Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuroendocrine Carcinoma Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Neuroendocrine Carcinoma Consumption by Country (2017-2022)

    • Figure United States Neuroendocrine Carcinoma Consumption and Growth Rate (2017-2022)

    • Table Europe Neuroendocrine Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure China Neuroendocrine Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure Japan Neuroendocrine Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure India Neuroendocrine Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neuroendocrine Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure Global Neuroendocrine Carcinoma Consumption Forecast by Country (2022-2028)

    • Figure United States Neuroendocrine Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neuroendocrine Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Neuroendocrine Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neuroendocrine Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neuroendocrine Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neuroendocrine Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Somatostatin Analogs Consumption and Growth Rate (2017-2022)

    • Figure Global Targeted Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Somatostatin Analogs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Targeted Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Neuroendocrine Carcinoma Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Neuroendocrine Carcinoma Export by Region (Top 5 Countries) (2017-2028)

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Neuroendocrine Carcinoma Product and Service

    • Table FHoffmann-La Roche (Foundation Year, Company Profile and etc.)

    • Table FHoffmann-La Roche Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table FHoffmann-La Roche Neuroendocrine Carcinoma Product and Service

    • Table Lexicon (Foundation Year, Company Profile and etc.)

    • Table Lexicon Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lexicon Neuroendocrine Carcinoma Product and Service

    • Table Teva (Foundation Year, Company Profile and etc.)

    • Table Teva Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Neuroendocrine Carcinoma Product and Service

    • Table Ipsen (Foundation Year, Company Profile and etc.)

    • Table Ipsen Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ipsen Neuroendocrine Carcinoma Product and Service

    • Table Abbvie (Foundation Year, Company Profile and etc.)

    • Table Abbvie Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbvie Neuroendocrine Carcinoma Product and Service

    • Table Jubilant (Foundation Year, Company Profile and etc.)

    • Table Jubilant Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jubilant Neuroendocrine Carcinoma Product and Service

    • Table Chiasma (Foundation Year, Company Profile and etc.)

    • Table Chiasma Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Chiasma Neuroendocrine Carcinoma Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Neuroendocrine Carcinoma Product and Service

    • Table Mateon (Foundation Year, Company Profile and etc.)

    • Table Mateon Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mateon Neuroendocrine Carcinoma Product and Service

    • Table Advanced Accelerator (Foundation Year, Company Profile and etc.)

    • Table Advanced Accelerator Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Advanced Accelerator Neuroendocrine Carcinoma Product and Service

    • Table Valeant (Foundation Year, Company Profile and etc.)

    • Table Valeant Neuroendocrine Carcinoma Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valeant Neuroendocrine Carcinoma Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US